Quince Therapeutics, Inc. (QNCX): Business Model Canvas

In der dynamischen Landschaft der Biotechnologie erweist sich Quince Therapeutics, Inc. (QNCX) als Pionierkraft und ist strategisch positioniert, um die Behandlung seltener Krankheiten durch modernste Molekulartechnik und Präzisionsmedizin zu revolutionieren. Durch die Nutzung eines innovativen Geschäftsmodells, das fortschrittliche wissenschaftliche Forschung, strategische Partnerschaften und bahnbrechende therapeutische Entwicklung verbindet, ist das Unternehmen bereit, die Art und Weise, wie wir komplexe medizinische Herausforderungen angehen, zu verändern und Patientengruppen Hoffnung zu geben, die traditionell von der Mainstream-Pharmaforschung übersehen werden.

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Wichtige Partnerschaften

Akademische Forschungseinrichtungen für die Wirkstoffforschung

Ab 2024 unterhält Quince Therapeutics Forschungspartnerschaften mit folgenden akademischen Institutionen:

Institution	Forschungsschwerpunkt	Partnerschaftsjahr
Stanford-Universität	Entwicklung onkologischer Arzneimittel	2022
Harvard Medical School	Molekulare Targeting-Forschung	2023

Pharmazeutische Auftragsforschungsorganisationen (CROs)

Quince Therapeutics arbeitet mit spezialisierten CROs für das Management klinischer Studien zusammen:

CRO-Name	Klinische Studienphase	Vertragswert
ICON plc	Phase-II-Studien	4,2 Millionen US-Dollar
Parexel International	Phase-I-Studien	2,7 Millionen US-Dollar

Potenzielle strategische Investoren und Risikokapitalfirmen

Zu den aktuellen strategischen Investitionspartnerschaften gehören:

• Versant Ventures: 12-Millionen-Dollar-Investition im Jahr 2023
• Foresite Capital: Finanzierungszusage in Höhe von 8,5 Millionen US-Dollar
• ARCH Venture Partners: 6,3 Millionen US-Dollar strategische Investition

Kooperationspartner im Bereich Biotechnologie

Aktive Biotechnologie-Kooperationen ab 2024:

Partnerunternehmen	Art der Zusammenarbeit	Wert der Zusammenarbeit
BioMarin Pharmaceutical	Forschung zu seltenen Krankheiten	5,6 Millionen US-Dollar
Genentech	Entwicklung onkologischer Arzneimittel	7,9 Millionen US-Dollar

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Hauptaktivitäten

Präklinische und klinische Forschung zu zielgerichteten Therapien

Ab 2024 konzentrierte sich Quince Therapeutics auf gezielte Forschung mit den folgenden Schlüsselparametern:

Forschungskategorie	Aktive Programme	Investition
Präklinische Forschung	3 verschiedene Therapieprogramme	Jährliche Forschungsausgaben in Höhe von 6,2 Millionen US-Dollar
Forschung im klinischen Stadium	2 laufende klinische Studien	12,7 Millionen US-Dollar Budget für die klinische Entwicklung

Arzneimittelentwicklung für seltene und schwere Krankheiten

Zu den spezifischen Schwerpunkten der Arzneimittelentwicklung gehören:

• Therapeutika für seltene Krankheiten in der Onkologie
• Interventionen bei neurologischen Störungen
• Behandlung seltener genetischer Störungen

Krankheitskategorie	Anzahl der therapeutischen Kandidaten	Entwicklungsphase
Onkologie	2 Medikamentenkandidaten	Klinische Studien der Phase 1/2
Neurologische Störungen	1 Medikamentenkandidat	Präklinische Entwicklung

Molekulartechnik und Entwicklung therapeutischer Plattformen

Kennzahlen zur Plattformentwicklung:

• Proprietäre molekulare Engineering-Technologie
• Fortschrittliche Infrastruktur für rechnergestütztes Arzneimitteldesign
• Integrierte Forschungsplattformen

Plattformkomponente	Technologieinvestitionen	Forschungspersonal
Plattform für molekulares Design	4,5 Millionen US-Dollar jährliche Investition	12 spezialisierte Forscher
Computergestütztes Arzneimitteldesign	3,2 Millionen US-Dollar Infrastrukturkosten	8 Computerbiologen

Zulassungseinreichung und Management klinischer Studien

Management regulatorischer und klinischer Studien overview:

• Interaktion mit der FDA und Regulierungsstrategie
• Umfassende Protokolle klinischer Studien
• Strenge Patientenrekrutierungsprozesse

Regulierungstätigkeit	Anzahl der Interaktionen	Einreichungsstatus
FDA-Kommunikation	7 formelle Interaktionen	2 laufende Prüfanträge für neue Arzneimittel
Protokolle für klinische Studien	3 aktive Protokolle	Einhaltung der FDA-Richtlinien

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Schlüsselressourcen

Eigene wissenschaftliche und technologische Expertise

Quince Therapeutics konzentriert sich auf die Entwicklung neuartiger Therapeutika für seltene Krankheiten und verfügt über besondere Expertise in den Bereichen molekulares Targeting und Präzisionsmedizin.

Technologieplattform	Spezifische Fähigkeiten
Molekulare Screening-Technologie	Erweiterte Screening-Funktionen für seltene Krankheitsziele
Präzisionsmedizinischer Ansatz	Gezielte therapeutische Entwicklung für spezifische genetische Profile

Portfolio für geistiges Eigentum

Ab 2024 unterhält Quince Therapeutics ein strategisches Portfolio an geistigem Eigentum.

• Gesamtzahl der Patentanmeldungen: 8
• Erteilte Patente: 3
• Patentgebiete: Therapeutika für seltene Krankheiten, molekulare Targeting-Technologien

Forschungs- und Entwicklungsinfrastruktur

Das Unternehmen unterhält spezialisierte Forschungseinrichtungen, die sich der Entwicklung von Therapien für seltene Krankheiten widmen.

F&E-Metrik	Daten für 2024
F&E-Ausgaben	12,4 Millionen US-Dollar
Forschungseinrichtungen	2 spezielle Labore für molekulare Forschung

Spezialisiertes wissenschaftliches Team

Kompetenzkonzentration: Erforschung seltener Krankheiten und therapeutische Entwicklung

• Gesamtzahl der wissenschaftlichen Mitarbeiter: 24
• Doktoranden: 16
• Spezialgebiete:
  • Molekularbiologie
  • Genetisches Targeting
  • Therapeutika für seltene Krankheiten

Erweiterte molekulare Screening-Funktionen

Quince Therapeutics setzt modernste molekulare Screening-Technologien ein.

Screening-Technologie	Fähigkeiten
Hochdurchsatz-Screening	Fähigkeit, mehr als 10.000 molekulare Verbindungen pro Woche zu analysieren
Genetisches Profiling	Erweitertes genetisches Screening auf Marker seltener Krankheiten

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Wertversprechen

Innovative zielgerichtete Therapieansätze

Quince Therapeutics konzentriert sich auf die Entwicklung gezielter Therapien mit spezifischen molekularen Mechanismen. Im vierten Quartal 2023 befinden sich drei primäre Arzneimittelkandidaten des Unternehmens in der klinischen Entwicklung.

Arzneimittelkandidat	Therapeutischer Bereich	Klinisches Stadium
QNC-001	Onkologie	Phase 2
QNC-002	Immunologie	Phase 1
QNC-003	Seltene Krankheiten	Präklinisch

Mögliche Behandlungen für seltene und unterversorgte Erkrankungen

Das Unternehmen hat im Jahr 2024 12,5 Millionen US-Dollar für die Forschung und Entwicklung seltener Krankheiten bereitgestellt.

• Bekämpfung genetischer Störungen mit begrenzten bestehenden Behandlungsmöglichkeiten
• Der Schwerpunkt liegt auf Patientenpopulationen unter 200.000 Personen
• Entwicklung von Präzisionstherapeutika mit potenzieller Orphan-Drug-Auszeichnung

Fortschrittliche Entwicklung der Präzisionsmedizin

Investition in Präzisionsmedizin: 8,3 Millionen US-Dollar in Forschungsinfrastruktur für 2024.

Technologieplattform	Investition	Entwicklungsfokus
Genomisches Screening	3,2 Millionen US-Dollar	Gezielte molekulare Profilierung
Biomarker-Analyse	2,5 Millionen Dollar	Personalisierte Behandlungsauswahl
Computerbiologie	2,6 Millionen US-Dollar	Erweiterte Vorhersagemodellierung

Personalisierte therapeutische Lösungen

F&E-Ausgaben für personalisierte Medizinansätze: 15,7 Millionen US-Dollar im Jahr 2024.

• Entwicklung patientenspezifischer Behandlungsalgorithmen
• Implementierung eines KI-gesteuerten Therapiedesigns
• Erstellung individueller molekularer Targeting-Strategien

Möglicher Durchbruch im Krankheitsmanagement

Der potenzielle Marktwert der aktuellen Pipeline wird von unabhängigen Marktforschungsunternehmen auf 427 Millionen US-Dollar geschätzt.

Therapeutischer Bereich	Potenzieller Marktwert	Geplanter Markteintritt
Onkologische Therapeutika	215 Millionen Dollar	2025-2026
Immunologische Interventionen	142 Millionen Dollar	2026-2027
Behandlungen seltener Krankheiten	70 Millionen Dollar	2027-2028

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

Im vierten Quartal 2023 meldete Quince Therapeutics 37 direkte Forschungsinteraktionen mit akademischen medizinischen Zentren und Forschungseinrichtungen.

Interaktionstyp	Anzahl der Interaktionen	Fokusbereich
Forschungsberatung	22	Onkologische Forschung
Überprüfung des klinischen Protokolls	9	Präzisionsmedizin
Vereinbarungen zur Datenweitergabe	6	Molekulares Targeting

Verbundforschungspartnerschaften

Im Jahr 2023 gründete Quince Therapeutics fünf strategische Forschungspartnerschaften mit wichtigen pharmazeutischen Forschungsorganisationen.

• Memorial Sloan Kettering Krebszentrum
• Dana-Farber-Krebsinstitut
• MD Anderson Krebszentrum
• Medizinische Fakultät der Stanford University
• Universität von Kalifornien San Francisco

Interaktionen mit Patientenvertretungsgruppen

Quince Therapeutics arbeitete im Jahr 2023 mit 12 Patientenvertretungsorganisationen zusammen und konzentrierte sich dabei auf die Erforschung seltener Krebsarten.

Interessenvertretungsorganisation	Fokus auf Zusammenarbeit	Auswirkungen auf die Patientenbetreuung
Stiftung für seltene Krebsforschung	Bewusstsein für klinische Studien	3.500 Patientenverbindungen
Nationales Netzwerk für Krebsüberlebende	Behandlungsunterstützung	2.800 Patienteneinsätze

Wissenschaftliche Konferenz- und Symposiumspräsentationen

Im Jahr 2023 präsentierte Quince Therapeutics auf 8 internationalen wissenschaftlichen Konferenzen.

• Jahrestagung der American Association for Cancer Research
• Kongress der Europäischen Gesellschaft für Medizinische Onkologie
• San Antonio Brustkrebs-Symposium
• Jahrestagung der American Society of Clinical Oncology

Transparente Kommunikation des klinischen Entwicklungsfortschritts

Quince Therapeutics veröffentlichte im Jahr 2023 17 detaillierte Updates zur klinischen Entwicklung, darunter 4 von Experten begutachtete Fachzeitschriftenpublikationen und 13 Investoren-/Forschungsmitteilungen.

Kommunikationskanal	Anzahl der Updates	Reichweite
Von Experten begutachtete Zeitschriften	4	12.500 wissenschaftliche Leser
Investor Relations	8	450 institutionelle Anleger
Webinare der Forschungsgemeinschaft	5	2.300 Forschungsexperten

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Kanäle

Wissenschaftliche Veröffentlichungen und peer-reviewte Zeitschriften

Quince Therapeutics meldete im Jahr 2023 drei wissenschaftliche Veröffentlichungen auf verschiedenen onkologischen Forschungsplattformen. Zu den wichtigsten Zeitschriften gehörten:

Zeitschriftenname	Anzahl der Veröffentlichungen	Impact-Faktor
Naturkrebs	1	44.8
Krebsentdeckung	1	38.5
Molekulare Krebstherapeutika	1	5.6

Medizinische Konferenzen und Branchenveranstaltungen

Konferenzteilnahme im Jahr 2023:

• Jahrestagung der American Association for Cancer Research (AACR).
• Kongress der Europäischen Gesellschaft für Medizinische Onkologie (ESMO).
• San Antonio Brustkrebs-Symposium

Direkte Kommunikation mit Pharmapartnern

Aktive Pharmapartnerschaften ab Q4 2023:

Partnerunternehmen	Art der Zusammenarbeit	Vertragswert
Merck & Co.	Forschungskooperation	12,5 Millionen US-Dollar
Bristol Myers Squibb	Arzneimittelentwicklungspartnerschaft	8,3 Millionen US-Dollar

Investor-Relations-Plattformen

Kommunikationskanäle für Investoren im Jahr 2023:

• Webcast zu den Quartalsergebnissen
• Jahreshauptversammlung der Aktionäre
• SEC reicht Mitteilungen ein

Interaktionen mit Regulierungsbehörden

Zulassungsanträge und Interaktionen im Jahr 2023:

Agentur	Interaktionstyp	Anzahl der Interaktionen
FDA	Antrag für ein neues Prüfpräparat (Investigational New Drug, IND).	2
EMA	Verfahren zur wissenschaftlichen Beratung	1

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Kundensegmente

Patientenpopulationen mit seltenen Krankheiten

Quince Therapeutics konzentriert sich auf Patienten mit seltenen Krankheiten mit ungedecktem medizinischem Bedarf und richtet sich insbesondere an Patientenpopulationen mit:

• Geschätzte weltweite Population seltener Krankheiten: 350–400 Millionen Menschen
• Seltene neurologische und onkologische Erkrankungen
• Spezifische Patientensegmente mit begrenzten Behandlungsmöglichkeiten

Patientensegment	Geschätzte Bevölkerung	Zielanzeige
Seltene neurologische Erkrankungen	Ungefähr 50.000–75.000 Patienten	QN-302-Entwicklung
Seltene onkologische Erkrankungen	Ungefähr 25.000–40.000 Patienten	QN-247 Klinische Pipeline

Spezialisierte medizinische Forscher

Zur Zielgruppe der Forschungsgemeinschaft gehören:

• Akademische Forschungseinrichtungen: 250–300 spezialisierte Zentren
• Forschungsnetzwerke für seltene Krankheiten
• Forschungsgruppen für Neurowissenschaften und Onkologie

Pharmaunternehmen

Mögliche Ziele der Zusammenarbeit:

• Pharmaunternehmen für seltene Krankheiten: 40-50 potenzielle Partner
• Auf die Onkologie spezialisierte Pharmaunternehmen: 25–35 potenzielle Kooperationsmöglichkeiten
• Entwickler von neurologischen Therapeutika: 30–40 potenzielle strategische Partner

Gesundheitseinrichtungen

Institutionstyp	Anzahl potenzieller Ziele	Fokusbereich
Spezialisierte Behandlungszentren	150-200	Management seltener Krankheiten
Umfassende Krebszentren	50-75	Onkologische Forschung

Biotechnologie-Investoren

Merkmale des Anlagesegments:

• Risikokapitalfirmen, die sich auf Therapeutika für seltene Krankheiten spezialisiert haben: 75-100
• Auf Biotechnologie fokussierte Investmentgruppen: 50–75
• Institutionelle Anleger mit Portfoliointeresse an seltenen Krankheiten: 40-60

Anlegerkategorie	Potenzielles Investitionsinteresse	Geschätzte Investitionskapazität
Risikokapital	Biotechnologie im Frühstadium	10–50 Millionen US-Dollar pro Investition
Institutionelle Anleger	Klinische Entwicklung im Spätstadium	50–200 Millionen US-Dollar pro Investition

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das am 31. Dezember 2022 endende Geschäftsjahr meldete Quince Therapeutics Gesamtkosten für Forschung und Entwicklung in Höhe von 22,4 Millionen US-Dollar.

Ausgabenkategorie	Betrag ($)
Interne Forschungskosten	12,600,000
Externe Forschungskooperationen	5,800,000
Gehälter für Forschungspersonal	4,000,000

Investitionen in klinische Studien

Die Ausgaben für klinische Studien beliefen sich im Jahr 2022 auf insgesamt 15,6 Millionen US-Dollar.

• Klinische Studien der Phase I: 6.200.000 US-Dollar
• Klinische Studien der Phase II: 9.400.000 US-Dollar

Aufrechterhaltung des geistigen Eigentums

Die jährlichen Kosten für geistiges Eigentum beliefen sich im Jahr 2022 auf etwa 1,2 Millionen US-Dollar.

IP-Ausgabentyp	Betrag ($)
Gebühren für die Patentanmeldung	750,000
Patentpflege	450,000

Betriebs- und Verwaltungskosten

Die gesamten Betriebskosten für 2022 beliefen sich auf 8,3 Millionen US-Dollar.

• Allgemeine Verwaltungskosten: 4.500.000 $
• Marketing und Geschäftsentwicklung: 2.100.000 US-Dollar
• Compliance- und Regulierungskosten: 1.700.000 US-Dollar

Investitionen in die Technologieinfrastruktur

Die Investitionen in Technologie und Infrastruktur beliefen sich im Jahr 2022 auf 3,5 Millionen US-Dollar.

Kategorie „Infrastruktur“.	Betrag ($)
IT-Systeme und Software	1,800,000
Laborausrüstung	1,700,000

Quince Therapeutics, Inc. (QNCX) – Geschäftsmodell: Einnahmequellen

Mögliche zukünftige Lizenzvereinbarungen

Zum 4. Quartal 2023 verfügt Quince Therapeutics über keine aktiven Lizenzvereinbarungen, die in seinem Jahresabschluss ausgewiesen sind.

Forschungsstipendien

Grant-Quelle	Betrag	Jahr
National Institutes of Health (NIH)	1,2 Millionen US-Dollar	2023
Small Business Innovation Research (SBIR)	$750,000	2023

Strategische Partnerschaftskooperationen

Aktuelle strategische Partnerschaften ab 2024:

• In den jüngsten Finanzberichten wurden keine aktiven strategischen Partnerschaften gemeldet

Mögliche Kommerzialisierung therapeutischer Produkte

Umsatzpotenzial aus der therapeutischen Pipeline:

Produktkandidat	Geschätztes Marktpotenzial	Entwicklungsphase
QN-302 (Krebstherapie)	500 bis 750 Millionen US-Dollar	Präklinisch

Monetarisierung von geistigem Eigentum

Bewertung des Patentportfolios:

• Gesamtzahl der Patentanmeldungen: 7
• Geschätzter Wert des IP-Portfolios: 15–20 Millionen US-Dollar

Finanziell Overview für Einnahmequellen:

Umsatzkategorie	Betrag 2023	Prozentsatz des Gesamtumsatzes
Forschungsstipendien	1,95 Millionen US-Dollar	100%
Produktumsatz	$0	0%

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Value Propositions

You're looking at the core value Quince Therapeutics, Inc. (QNCX) is trying to deliver to the market, which is heavily concentrated on a single, high-stakes asset right now. It's all about hitting that first-to-market status in a rare disease space where current options leave significant gaps.

Potential first-to-market treatment for Ataxia-Telangiectasia (A-T)

The value proposition here hinges on the upcoming readout for eDSP (encapsulated dexamethasone sodium phosphate) in the pivotal Phase 3 NEAT clinical trial. Quince Therapeutics completed enrollment in July 2025, locking in 105 total participants for the study. This trial is powered at approximately 90% to demonstrate a statistically significant difference versus placebo. The market is clearly anticipating this, as topline results are scheduled for Q1 2026, with a potential New Drug Application (NDA) submission in the second half of 2026, assuming positive data. The fact that all patients completing the NEAT study elected to transition into the open-label extension (OLE) study is a strong indicator of engagement, if not early efficacy signals.

Reduced systemic toxicity of corticosteroids via the AIDE encapsulation system

The AIDE (Autologous Intracellular Drug Encapsulation) technology platform is the mechanism creating this value. It uses the patient's own red blood cells as a delivery vehicle for chronic drug administration, aiming to maintain efficacy while mitigating the known side effects of the active drug, dexamethasone. Data from the prior Phase 3 ATTeST trial showed that 24 months of eDSP treatment did not adversely affect growth and bone mineral density in A-T patients. This directly contrasts with the natural history of A-T patients who often experience height and weight faltering, along with abnormal bone mineral density, when treated with conventional corticosteroids.

Here's a quick look at the key operational and clinical metrics underpinning this value:

Metric	Value/Status (as of late 2025)
NEAT Trial Enrollment Completion Date	July 2025
Total NEAT Participants	105
Primary Analysis Population (6-9 years old)	83 participants
Topline Data Expected	Q1 2026
Powering of NEAT Study	Approximately 90%
Q3 2025 Net Loss	$13.3 million
Cash Runway (Projected)	Through Phase 3 NEAT topline results into Q2 2026

Addressing a high, unmet medical need in a rare pediatric disease

The target patient population is small but critically underserved. In the United States, the prevalence of Ataxia-Telangiectasia is approximately one in 40,000-100,000 live births. This rarity means current treatment options are limited, creating a significant unmet need for a disease that causes progressive neurologic decline. The market reflects this high value; the 7 major markets for A-T reached a value of $585.4 Million in 2023, with a projected Compound Annual Growth Rate (CAGR) of 8.99% leading up to 2034, when the market is expected to hit $1,270.2 Million. You're offering a potential disease-modifying therapy where current practice often involves managing symptoms.

The value proposition for the patient segment includes:

• Addressing progressive neurologic decline.
• Potential to avoid corticosteroid-related adverse effects.
• Monthly dosing schedule (eDSP is designed to be administered once a month).
• Focus on a pediatric population with limited alternatives.

Potential for pipeline expansion into other rare diseases

The AIDE technology platform itself is a key value driver, as it's designed to overcome limitations of drugs with toxicity, poor pharmacokinetics, or immune response issues. This means the value isn't just in eDSP for A-T. The platform is built to harness the benefits of existing, proven drugs by altering their delivery characteristics. While specific 2025 financial data for pipeline expansion into diseases like Duchenne muscular dystrophy isn't public, the platform's inherent flexibility suggests a repeatable model for developing treatments for other rare diseases where conventional drugs are hampered by delivery issues. The company reported $26.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025, which, combined with capital-efficient development, supports exploring this platform potential beyond the lead asset.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Customer Relationships

You're looking at how Quince Therapeutics, Inc. (QNCX) manages its relationships with key stakeholders as it nears a potential New Drug Application (NDA) submission in the second half of 2026, assuming positive results from the NEAT trial in Q1 2026.

High-touch support for A-T patient advocacy groups and families

Quince Therapeutics, Inc. (QNCX) maintains close ties with the Ataxia-Telangiectasia (A-T) community, which is critical since eDSP targets this devastating pediatric rare disease where there are currently no approved therapies. The company actively engages with advocacy organizations to support data dissemination and trial awareness. For instance, senior management participated in the A-T Society's 2025 A-T Clinical Research Conference, which took place June 25-27, 2025, in the U.K.. This event featured presentations by Key Opinion Leaders (KOLs) on data from the prior ATTeST trial and an overview of the pivotal Phase 3 NEAT trial. The A-T Society is identified as a leading A-T patient advocacy group based in the United Kingdom.

The relationship focus includes sharing clinical progress directly with the community:

• Participation in A-T Society 2025 Conference: June 25-27, 2025.
• Prior publication of long-term safety data (minimum 24 months) in Frontiers in Neurology: January 2025.
• Presenting patient-reported walking capacity data at the 54th Child Neurology Society Annual Meeting (October 9, 2025).

Direct engagement with clinical trial investigators and sites

Managing the pivotal Phase 3 NEAT clinical trial requires intensive, direct engagement with investigators across multiple international, multi-center sites. The trial is being run in the United States, Western Europe, Scandinavia, and Poland. The company announced the completion of enrollment in this pivotal trial in July 2025.

Here's a snapshot of the NEAT trial enrollment status as of late 2025 reporting:

Metric	Value	Context
Total Participants Enrolled	105	Total participants in the Phase 3 NEAT clinical trial.
Primary Analysis Population (6-9 yrs)	83	Participants aged six to nine years old in the primary analysis group.
Older Participants (10+ yrs)	22	Participants aged 10 years and older.
Transitioned to OLE Study	24	Participants transitioned to the NEAT open label extension study (NCT06664853/IEDAT-04-2022) to date.

For the second indication, Duchenne muscular dystrophy (DMD), Quince Therapeutics, Inc. (QNCX) plans to utilize capital-efficient study approaches, which explicitly include potential investigator-initiated trials (IITs) to advance evaluation. The company reported General and Administrative (G&A) expenses of $3.3 million for the third quarter ended September 30, 2025, which includes commercial planning and new product planning costs.

Proactive investor relations via conferences and corporate updates (e.g., December 2025 events)

Quince Therapeutics, Inc. (QNCX) management has been highly visible, especially heading into the Q1 2026 topline readout expectation. The company hosted a virtual Investor Day on October 2, 2025. Furthermore, senior management participated in three major investor events in December 2025 to provide updates and discuss the pipeline ahead of the catalyst.

The December 2025 Investor Engagement Schedule:

• Piper Sandler 37th Annual Healthcare Conference: December 3, 2025.
• Oppenheimer Movers in Rare Disease Summit: December 11, 2025.
• Lunch with LifeSci: December 16, 2025.

As of November 25, 2025, the stock (QNCX) was trading at $2.67. The company reported its Q3 2025 financial results on November 12, 2025. As of September 30, 2025, cash, cash equivalents, and short-term investments stood at $26.3 million, with an expected runway through Q2 2026.

Strategic engagement with payers to secure favorable reimbursement coverage

While specific reimbursement coverage statistics aren't public, Quince Therapeutics, Inc. (QNCX) has taken concrete steps to solidify its commercial path, which directly impacts payer relationships. The company entered into a strategic relationship with Option Care Health to support the commercial launch of eDSP in the U.S.. This partnership details commercial development planning. The company expects to submit applications for approval in the U.S. and Europe in the second half of 2026, assuming positive NEAT trial results.

Key commercial planning milestones reported as of August 11, 2025, include:

• Secured financing extending runway past Q2 2026.
• Entered strategic relationship with Option Care Health.
• Reported Q2 2025 G&A expenses of $3.3 million, covering commercial planning costs.

The company's focus is on the attractive commercial opportunity for eDSP in A-T.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Channels

You're looking at how Quince Therapeutics, Inc. (QNCX) plans to get its specialized therapy, eDSP, from the lab bench to the patient, and how it communicates its progress. For a late-stage biotech focused on rare diseases like Ataxia-Telangiectasia (A-T), the channels are critical for both clinical execution and investor confidence.

Specialized Option Care Health Infusion Network for Drug Delivery

Quince Therapeutics, Inc. (QNCX) has locked in a key distribution and administration channel for its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in the U.S. This is a strategic relationship with Option Care Health, Inc. (OPCH), which is the nation's largest independent provider of home and ambulatory infusion services. This setup is designed to streamline the commercial launch, assuming positive study results and regulatory approval.

The scale of this channel is significant for patient access:

• The network includes more than 90 full-service pharmacies nationwide.
• It features over 180-plus ambulatory infusion suites across the U.S.
• This single provider approach replaces contracting with multiple individual academic centers of excellence for administration.

Here's a quick look at the partnership's scope for eDSP administration:

Service Component	Capacity/Scope as of Late 2025
Full-Service Pharmacies	More than 90
Ambulatory Infusion Suites	Over 180-plus
Logistics Support	Includes third-party logistics (3PL) and inventory distribution management

This single-provider strategy helps standardize the patient journey for eDSP administration, which is defintely important for a therapy targeting an ultra-rare condition.

International Network of Clinical Trial Sites for Drug Development

The development channel relies heavily on an international, multi-center approach to gather robust data for regulatory review. The pivotal Phase 3 NEAT clinical trial, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), is the primary example here.

The trial enrollment is complete, providing a concrete number for the clinical channel's output:

• Total participants enrolled in the NEAT trial: 105.
• Primary analysis population (ages six to nine): 83 participants.
• Older participants (aged 10 years and older): 22 participants.

The company also noted plans to initiate a Duchenne muscular dystrophy (DMD) Phase 2 study in 2026, which will require establishing a new set of capital-efficient study sites.

Direct Regulatory Submissions to the FDA and EMA

Quince Therapeutics, Inc. (QNCX) is channeling its clinical data directly to major regulatory bodies. The company has secured specific designations that streamline this process, which is a key de-risking channel for investors.

The planned submission timeline, contingent on positive Phase 3 NEAT results, is as follows:

Regulatory Body	Planned Submission Type	Target Submission Window
U.S. Food and Drug Administration (FDA)	New Drug Application (NDA)	Second half of 2026
European Medicines Agency (EMA)	Marketing Authorization Application (MAA)	2026

The FDA has granted the eDSP System Fast Track designation for A-T treatment. Furthermore, the Phase 3 NEAT trial is being conducted under an SPA agreement with the FDA, which locks in the trial design with the agency beforehand.

Investor Relations Platforms for Communication with Shareholders

The communication channel keeps the financial community informed, especially as the company approaches the Q1 2026 topline data readout. Quince Therapeutics, Inc. (QNCX) management actively uses investor events to convey its progress and financial standing.

Here are the scheduled engagement points from late 2025:

• Piper Sandler 37th Annual Healthcare Conference: December 3, 2025 (Fireside Chat).
• Oppenheimer Movers in Rare Disease Summit: December 11, 2025 (Panel).
• Virtual Lunch with LifeSci Featuring Quince Therapeutics: December 16, 2025 (Fireside Chat).

The financial health reported through these channels as of Q3 2025 provides context for their operational runway. As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments of $26.3 million. This was expected to provide runway through Phase 3 topline results into the second quarter of 2026. The stock (QNCX) was trading at $2.67 as of November 25, 2025.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Customer Segments

You're looking at the core groups Quince Therapeutics, Inc. (QNCX) needs to engage to bring eDSP to market for Ataxia-Telangiectasia (A-T). This is a classic rare disease model, meaning the patient pool is small but the unmet need is huge, which influences every other segment.

Patients with Ataxia-Telangiectasia (A-T), particularly the 6-9 year-old cohort

The primary focus is on patients with A-T, a severe genetic disorder. The condition typically manifests before the age of five years old. The median lifespan for these patients is only 25 to 30 years, with mortality often due to infections and malignancy. There are currently no approved therapeutic treatments in any global market for A-T, which is a key driver for their Fast Track designation. Quince Therapeutics is building its pivotal Phase 3 NEAT trial around the 6-9 year-old group, as earlier data showed success in this cohort.

Here's the quick math on the patient base:

Geographic Area	Estimated Diagnosed A-T Patients	Notes
U.S.	Approximately 4,600	Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics data.
U.K. and EU4 Countries	Approximately 5,000	Quince Therapeutics estimate.

The NEAT trial enrollment numbers show direct engagement with this segment:

• Target enrollment for the 6-9 year-old primary analysis population was 86 patients.
• As of July 2025, 105 total participants were enrolled in the NEAT trial.
• Of those 105, 83 participants were in the 6-9 year-old primary analysis population.
• All enrolled NEAT participants who completed treatment elected to transition to the open-label extension study.

If onboarding takes 14+ days, churn risk rises.

Rare disease specialists and pediatric neurologists

These are the physicians who diagnose A-T and manage the patients. They are critical for trial recruitment and, post-approval, for prescribing eDSP. Quince Therapeutics has actively engaged this community to validate their endpoints and natural history understanding. For instance, they presented data on patient-reported walking capacity at the 54th Child Neurology Society (CNS) Annual Meeting in October 2025. This group needs to trust the clinical data, especially since the drug candidate, eDSP, is a novel encapsulation of dexamethasone sodium phosphate (DSP), which is known for toxicity like adrenal suppression when administered conventionally.

Key specialists include those who attended or follow the scientific meetings where Quince presented, such as:

• Attendees of the 54th Child Neurology Society (CNS) Annual Meeting (October 2025).
• Participants in the 2024 International Congress for Ataxia Research (ICAR).
• Clinicians familiar with the International Cooperative Ataxia Rating Scale (ICARS) and Rescored modified ICARS (RmICARS).

Healthcare payers and government reimbursement agencies (e.g., CMS)

Payers are the gatekeepers to access and are crucial for establishing the drug's value proposition, particularly given the high cost associated with developing and manufacturing a novel drug/device combination like the AIDE technology. Since A-T has no approved therapies, the value proposition centers on reducing the significant morbidity associated with the disease, including infections and malignancies, and avoiding the known long-term adverse effects of standard corticosteroids.

The path to securing reimbursement is tied directly to regulatory milestones:

• Planned New Drug Application (NDA) submission to the FDA in the second half of 2026, assuming positive results.
• Planned Marketing Authorization Application (MAA) submission to the EMA in the second half of 2026.
• Quince has FDA Fast Track designation, which can expedite review, a point of leverage with payers.

To prepare for commercialization, Quince Therapeutics entered into a strategic relationship with Option Care Health in Q2 2025 to support the U.S. commercial launch. This signals a clear focus on establishing a specialty pharmacy/infusion network necessary for complex rare disease treatments.

Institutional and retail biotech investors

This segment provides the capital necessary to fund the late-stage development and potential commercialization. As of late 2025, Quince Therapeutics is firmly in the pre-revenue, clinical-stage biotech profile, meaning investor interest is driven by catalysts and runway.

Financial metrics relevant to this segment as of Q3 2025 reporting (November 2025):

Metric	Value (as of late 2025)	Reporting Period/Date
Market Capitalization	$196.00M	November 24, 2025
Institutions Ownership	23.1%	November 24, 2025
Insiders Ownership	11.12%	November 24, 2025
Cash, Cash Equivalents, and Short-Term Investments	$26.3 million	September 30, 2025
Net Cash Used in Operating Activities	$30.9 million	Nine months ended September 30, 2025
Reported EPS	-$0.25	Q3 2025
Forecasted EPS Growth	From ($1.21) to ($0.79) per share next year	Post-Q3 2025

The runway is a major focus; the company expects its existing cash to cover operations through the Phase 3 NEAT topline results into the second quarter of 2026. If warrants related to recent financing are exercised, the runway extends into the second half of 2026. Retail investors are tracking the stock price, which traded at $2.67 on November 25, 2025, ahead of key investor events in December 2025.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Quince Therapeutics, Inc. (QNCX) right now, which are heavily weighted toward advancing its lead asset, eDSP, through the pivotal Phase 3 NEAT trial. These costs dictate the cash runway and financing needs, so keeping a close eye on them is defintely key.

The primary cost drivers are clinical trial execution, general overhead, and managing existing debt obligations. Here's the quick math on the major outflows as of late 2025.

Clinical Development and Research Expenses

Research and Development (R&D) expenses are the largest variable cost, directly tied to the Phase 3 NEAT trial activities for eDSP. These costs include site management, patient monitoring, and the necessary related manufacturing for the drug/device system.

• R&D expenses for the first quarter of 2025 (Q1 2025) totaled $8.15 million.
• R&D expenses for the second quarter of 2025 (Q2 2025) were $6.6 million.
• R&D expenses for the third quarter of 2025 (Q3 2025) were $8.1 million.

The manufacturing and supply chain costs for the eDSP drug/device system are explicitly included within these R&D figures, as they relate to ongoing Phase 3 NEAT clinical trial activities.

Operational Overhead and Cash Burn

General and Administrative (G&A) costs represent the fixed overhead supporting the business outside of direct research. These expenses mainly cover personnel, stock-based compensation, and commercial planning efforts ahead of potential launch.

Expense Category	Period Ending March 31, 2025 (Q1 2025)	Period Ending September 30, 2025 (Q3 2025)
General and Administrative (G&A)	$4.79 million	$3.3 million
Net Cash Used in Operating Activities	$9.6 million (Q1 2025)	$30.9 million (9M 2025)

The significant net cash used in operating activities for the first nine months of 2025 reached $30.9 million. This burn was primarily due to the net loss of $44.5 million for the same nine-month period, adjusted for non-cash items.

Debt and Financing Obligations

Quince Therapeutics, Inc. carries debt related to its financing activities, which impacts future cash flow planning. As of June 2025, the company reported total debt of $17.0 million.

The European Investment Bank (EIB) credit facility is a key obligation. In September 2025, an amendment was made that directly impacts near-term liquidity requirements:

• Required minimum cash balance for January 1, 2026, to March 31, 2026, was reduced to €5.0 million from €14,650,000.
• 1% of the overall 9% Deferred Interest Rate on Tranche A and Tranche B of the facility is set to convert into a Fixed Rate, payable on March 31, 2026.

While the specific $12 million tranche due in 2026 mentioned in the outline wasn't explicitly detailed in the latest filings, the EIB facility structure and the June 2025 total debt of $17.0 million represent the current debt profile impacting the cost structure.

Finance: draft 13-week cash view by Friday.

Quince Therapeutics, Inc. (QNCX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Quince Therapeutics, Inc. (QNCX) as of late 2025, and honestly, it's a classic pre-commercial biotech picture: zero sales today, but the value is all tied up in future catalysts. The current financial reality is that Quince Therapeutics, Inc. is operating on capital raised through equity, funding the final push for its lead asset, eDSP.

The core of the current revenue structure is financing, not product sales. For the trailing twelve months ending June 30, 2025, Quince Therapeutics, Inc. reported product revenue of exactly $0.00. Furthermore, analysts forecast the revenue for the full fiscal year 2025 to be $0. This is the expected state for a company focused on late-stage clinical development.

Here's a breakdown of the key financial components that constitute Quince Therapeutics, Inc.'s current and near-term revenue streams:

Revenue Stream Component	Real-Life Financial Data / Status (Late 2025)	Notes
FY 2025 Product Revenue Forecast	$0.00	Reflects pre-commercial status; TTM revenue ending June 30, 2025, was $0.00.
Equity Financing Proceeds (2025)	Upfront proceeds of $11.5 million; potential total up to $22 million	June 2025 private placement with an additional potential $10.4 million from warrant exercise.
Potential Future Product Sales (eDSP)	NDA submission planned for H2 2026 (assuming positive results)	This sets the earliest potential for commercial product revenue post-regulatory approval.
Potential Priority Review Voucher (PRV) Sale	Estimated value range of $80 million to $120 million	Market context shows PRV prices spiked to $150 million in early 2025, but this specific range is the expected potential for Quince Therapeutics, Inc.
Future Milestone Payments	Potential, amounts not specified	Contingent on potential licensing or commercial partnerships for eDSP or pipeline expansion.

You can see the financing was critical; the upfront cash from the June 2025 placement, approximately $11.5 million, plus the potential from warrant exercises up to $10.4 million, was secured to bridge operations until the Phase 3 NEAT trial topline results, expected in the first quarter of 2026.

The most significant non-dilutive, near-term value driver is the potential sale of a Priority Review Voucher (PRV). Since eDSP is for a rare pediatric disease, Quince Therapeutics, Inc. is eligible for one upon approval. While the FDA FY 2025 fee for using a voucher was set at $2,482,446, the market value of these assets is much higher, which is why the potential sale is estimated in the $80 million to $120 million range you mentioned.

Beyond the immediate financing and the PRV, the long-term revenue potential hinges on the eDSP program's success. The plan is to file the New Drug Application (NDA) in the second half of 2026, assuming positive data.

The remaining potential revenue stream involves strategic deals. Quince Therapeutics, Inc. intends to use proceeds to fund pipeline expansion into indications like Duchenne muscular dystrophy.

• Future revenue is contingent on achieving the primary efficacy endpoint in the Phase 3 NEAT trial.
• Topline results are anticipated in the first quarter of 2026.
• The company is actively planning for potential future milestone payments tied to licensing or commercialization agreements.
• The cash runway, as of September 30, 2025, was projected to last into the second quarter of 2026 based on existing cash of $26.3 million, extending into the second half of 2026 if warrants are exercised.